Analysis of withdrawal of rofecoxib-cyclooxygenase-2 specific inhibitor
- VernacularTitle:高选择性COX-2抑制剂罗非昔布撤市分析
- Author:
Qin LI
;
Rui WANG
;
Kun CHEN
- Publication Type:Journal Article
- Keywords:
rofecoxib;
celecoxib;
COX-2 inhibitor;
cardiovascular effect;
withdrawal
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2000;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Rofecoxib, a COX-2 specific inhibitor, is approved for treatment of osteoarthritis, acute pain and primary dysmenorrhea. On September 30, 2004, Merck announced the voluntary worldwide withdrawal of rofecoxib (Vioxx). This paper reviewed the pharmacological actions of the COX-2 specific inhibitors and the characterization, premarket study, clinical application and side-effects of rofecoxib and analyzed the withdrawal of rofecoxib.
